Cancer Discov:阻断TIGIT有望改善靶向CD19的CAR-T细胞疗法对非霍奇金淋巴瘤的疗效

2022-05-28 生物谷 生物谷

研究发现用CAR-T细胞疗法阻断TIGIT可以在体内研究中提高治疗效果。

在一项新的研究中,来自梅奥诊所、凯斯西储大学和克利夫兰医学中心的研究人员研究了接受靶向CD19的嵌合抗原受体(CAR)T细胞(CAR-T)疗法治疗的非霍奇金淋巴瘤患者的缓解率下降的原因。相关研究结果于2022年5月12日在线发表在Cancer Discovery期刊上,论文标题为“Sequential single cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin's lymphoma”。

论文共同作者、梅奥诊所癌症中心研究员Tae Hyun Hwang博士说,“CAR-T细胞疗法是一种有前途的非霍奇金淋巴瘤治疗方法,特别是对于复发的患者或对先前疗法没有反应的患者。”

然而,Hwang博士说,近期的长期随访数据表明,非霍奇金淋巴瘤患者的CAR-T细胞疗法的成功率可能正在下降。Hwang博士说,“在这种情况下,持久的缓解率在30%~40%之间,因此,确定一种预测性生物标志物来衡量CAR-T细胞的抵抗性是至关重要的,这样我们就可以更好地将患者与有效的疗法相匹配。”

论文通讯作者、凯斯西储大学的David Wald博士说,“我们研究的总体目标是支持精准肿瘤治疗。新的治疗策略将帮助我们提高CAR-T细胞疗法在非霍奇金淋巴瘤患者中的疗效。”

Hwang博士说,“我们的团队猜测在对治疗有反应的患者和没有反应的患者之间,CAR-T细胞会有不同的分子模式。”他说,他的团队使用创新的计算和实验方法来确定这些模式。

图片来自Unsplash/CC0 Public Domain。

这些作者在CAR-T细胞被注射给患者之前,以及在被注入患者体内后的多个时间点,产生了单细胞RNA和蛋白测序数据。Hwang博士说,这项新的研究产生了133000多个单细胞表达谱,他们利用这些数据开发和应用计算方法来分析与治疗反应有关的CAR-T细胞的单细胞水平RNA或蛋白表达模式。

利用这些计算方法,这些作者发现一个名为TIGIT的基因在对CAR-T细胞疗法没有反应的患者体内注射的CAR-T细胞中高度表达。他们还证实TIGIT驱动CAR-T细胞衰竭和功能失调,他们发现用CAR-T细胞疗法阻断TIGIT可以在体内研究中提高治疗效果。

Hwang博士说,“如果我们的发现能够在前瞻性临床试验中得到验证,我们的TIGIT阻断策略与CAR-T细胞疗法可能会改善目前非霍奇金淋巴瘤患者对CAR-T细胞疗法的反应,也可能改善患者的生存率。”

参考资料:

1. Zachary Jackson et al. Sequential single cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin's lymphoma. Cancer Discovery, 2022, doi:10.1158/2159-8290.CD-21-1586.

2. Researchers seek to improve success of chimeric antigen receptor-T cell therapy in non-Hodgkin lymphoma
https://medicalxpress.com/news/2022-05-success-chimeric-antigen-receptor-t-cell.html

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781491, encodeId=1e2e1e8149190, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Jan 23 12:21:19 CST 2023, time=2023-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710309, encodeId=39921e10309c4, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Aug 18 14:21:19 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013882, encodeId=a2922013882b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 10:21:19 CST 2023, time=2023-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291588, encodeId=2fe2129158857, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416480, encodeId=a11d141648093, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478072, encodeId=e8b614e80727c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587947, encodeId=139e158e9471a, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=)]
    2023-01-23 仁者大医
  2. [GetPortalCommentsPageByObjectIdResponse(id=1781491, encodeId=1e2e1e8149190, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Jan 23 12:21:19 CST 2023, time=2023-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710309, encodeId=39921e10309c4, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Aug 18 14:21:19 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013882, encodeId=a2922013882b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 10:21:19 CST 2023, time=2023-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291588, encodeId=2fe2129158857, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416480, encodeId=a11d141648093, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478072, encodeId=e8b614e80727c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587947, encodeId=139e158e9471a, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1781491, encodeId=1e2e1e8149190, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Jan 23 12:21:19 CST 2023, time=2023-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710309, encodeId=39921e10309c4, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Aug 18 14:21:19 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013882, encodeId=a2922013882b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 10:21:19 CST 2023, time=2023-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291588, encodeId=2fe2129158857, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416480, encodeId=a11d141648093, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478072, encodeId=e8b614e80727c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587947, encodeId=139e158e9471a, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1781491, encodeId=1e2e1e8149190, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Jan 23 12:21:19 CST 2023, time=2023-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710309, encodeId=39921e10309c4, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Aug 18 14:21:19 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013882, encodeId=a2922013882b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 10:21:19 CST 2023, time=2023-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291588, encodeId=2fe2129158857, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416480, encodeId=a11d141648093, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478072, encodeId=e8b614e80727c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587947, encodeId=139e158e9471a, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1781491, encodeId=1e2e1e8149190, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Jan 23 12:21:19 CST 2023, time=2023-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710309, encodeId=39921e10309c4, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Aug 18 14:21:19 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013882, encodeId=a2922013882b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 10:21:19 CST 2023, time=2023-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291588, encodeId=2fe2129158857, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416480, encodeId=a11d141648093, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478072, encodeId=e8b614e80727c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587947, encodeId=139e158e9471a, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=)]
    2022-05-30 dingxiaobo
  6. [GetPortalCommentsPageByObjectIdResponse(id=1781491, encodeId=1e2e1e8149190, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Jan 23 12:21:19 CST 2023, time=2023-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710309, encodeId=39921e10309c4, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Aug 18 14:21:19 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013882, encodeId=a2922013882b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 10:21:19 CST 2023, time=2023-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291588, encodeId=2fe2129158857, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416480, encodeId=a11d141648093, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478072, encodeId=e8b614e80727c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587947, encodeId=139e158e9471a, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1781491, encodeId=1e2e1e8149190, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Jan 23 12:21:19 CST 2023, time=2023-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710309, encodeId=39921e10309c4, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Aug 18 14:21:19 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013882, encodeId=a2922013882b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 10:21:19 CST 2023, time=2023-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291588, encodeId=2fe2129158857, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416480, encodeId=a11d141648093, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478072, encodeId=e8b614e80727c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587947, encodeId=139e158e9471a, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon May 30 13:21:19 CST 2022, time=2022-05-30, status=1, ipAttribution=)]
    2022-05-30 yankaienglish

相关资讯

Clin Cancer Res:采用抗CD79B抗体药物偶联物DCDS0780A治疗非霍奇金淋巴瘤

抗CD79B抗体药物偶联物 DCDS0780A 用于B细胞非霍奇金淋巴瘤患者可诱导获得深度缓解。

Clin Cancer Res:维奈托克单药治疗复发/难治性非霍奇金淋巴瘤的长期随访结果

复发/难治性非霍奇金淋巴瘤患者采用维奈托克单药治疗可获得持久的缓解

Br J Cancer:淋巴瘤患者诊断延迟与潜在合并症相关

非霍奇金淋巴瘤(NHL)是一种异质性疾病,包括60多种具有不同组织学模式的实体状态,约占所有淋巴瘤的80%-90%。

European Radiology:CT放射组学列线图对腭扁桃体鳞状细胞癌和非霍奇金淋巴瘤的鉴别诊断

鳞状细胞癌(SCC)是头颈部最常见的恶性肿瘤,而非霍奇金淋巴瘤(NHL)是第二常见的肿瘤。腭扁桃体是头颈部SCC和NHL最常见的解剖学部位。这

Clin Cancer Res:复发/转移性非霍奇金淋巴瘤采用维奈托克治疗的长期预后

维奈托克单一疗法具有可控的安全性,并在FL、MCL、WM 和MZL患者的亚组中实现持久缓解

通用型CAR-T细胞CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤,初步结果达到100%ORR和80%CR

2022年5月12日,Caribou Biosciences公司宣布,其基于CRISPR基因编辑改造的通用型CAR-T疗法CB-010,在治疗复发/难治性B细胞非霍奇金淋巴瘤患者的1期临床试验中获得积